How Effective Is Hypertension Treatment Device?
InterCure announced the findings of new studies and analysis highlighting RESPeRATE -- the only medical device cleared by the FDA and CE-approved for the treatment of hypertension. Five posters will be presented at the European Society of Hypertension meeting (ESH) in Berlin beginning June 14, 2008. Two of the five posters focus on RESPeRATE's effect on blood pressure as measured by 24-hour ambulatory blood pressure monitoring. Three of the posters also present new findings in the emerging field of obtaining vascular risk parameters from blood pressure measurements. The fifth poster demonstrates the benefits of RESPeRATE in patients with chronic heart failure.
"InterCure is making great strides within the European marketplace and has received a tremendous response from both the scientific and consumer communities," says Erez Gavish, president and CEO of InterCure. "The continued clinical interest is producing a constant drumbeat of validation for RESPeRATE, paving the path for the successful charge into retail outlets in Europe and the U.S. and building on the more than 100,000 hypertension sufferers who have already adopted RESPeRATE as a treatment for their hypertension."
Results of the findings related to RESPeRATE are being presented as posters at ESH and are as follows:
Share this content.
-- PS26/WED/05 -- A study performed in Turkey, led by Prof. Erdine, Department of Cardiology, Istanbul University, demonstrated that the RESPeRATE device provides daytime and nighttime blood pressure reductions as measured by 24-hour ambulatory monitoring. The study also demonstrated that patients were compliant with the device and that no adverse side effects were reported.
-- PS33/THU/01 -- Pooled results from two separate studies led by Profs. Rosenthal and the Erdine study (above), utilizing 24-hour ambulatory blood pressure monitoring demonstrated that RESPeRATE benefits uncontrolled-hypertension sufferers. The analysis demonstrated a clinically significant blood pressure reduction throughout both daytime and nighttime. RESPeRATE was also found to independently reduce high values of a risk-associated arterial property (S-D slope/AASI) derived from the relationship between systolic and diastolic pressures.
-- PS34/MON/08 -- Data analysis led by Dr. Benjamin Gavish, chief scientific officer, InterCure, Ltd., of a study performed in Italy, conducted by Prof. Gianfranco Parati, explored, for the first time, the linear relationships between systolic and diastolic blood pressure from beat-to-beat measurements. The derived risk-related parameters (S-D slope and AASI) are acutely influenced by breathing patterns and neck suction.
-- PS34/MON/18 -- An Israeli study, conducted by Dr. Iddo Ben-Dov and Prof. Michael Burzstyn from Hadassah Medical Center, and Dr. Benjamin Gavish, concluded that the ratio of systolic to diastolic blood pressure variability is shown to be a blood pressure-independent predictor of mortality, associated with the linear relationship between systolic and diastolic pressures.
-- PS18/WED/58 -- An Italian, randomized controlled study, led by Prof. G. Parati from the University of Milan-Bicocca concluded that device- guided paced breathing at home is feasible and improves prognostically relevant clinical and instrumental parameters in heart failure patients. It is recommended as an additional long-term treatment program for these patients.